[English]  [Pусский]  [中文]  
 
ctt-journal > Darskaya et al. (Abstract)

Darskaya et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract70

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Results of autologous stem cell transplantation in patients with multiple myeloma

Elena I. Darskaya, Vladimir N. Vavilov, Nina E. Osipova, Elena V. Babenko, Maria A. Estrina, Boris V. Afanasyev

R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, St. Petersburg, Russia

Correspondence: Elena I. Darskaya, R.M. Gorbacheva Memorial Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, 6/8, Tolstoy str., St. Petersburg, 197022, Russia, E-mail: edarskaya@spam is badmail.ru

Abstract

We retrospectively analyzed the outcome of 73 patients with multiple myeloma who received single (n=46) and double (n=27) autologous hematopoietic stem cells transplantation (auto-HSCT) as upfront (n=47) and second line (n=27) therapy. Induction therapy included VAD (vincristin, doxorubicin, dexamethason), Ida-D (idarubicin, dexamethason), or bortezomib-based and other protocols in 40, 28, and 5 patients respectively. Disease status at auto-HSCT was VGPR (n=26), PR (n=31), SD (n=8), and PD/RD (n=8).

Results: Induction therapy with a bortezomib-based combination improves overall survival compared to other induction therapy. Overall survival at 5 years was 60% of patients who received single auto-HSCT as upfront and 45% in patients who received auto-HSCT as second line therapy (p=0.0069). Overall survival at 10 years was similar in both groups (45%). Event-free survival at 3 years was also better after upfront auto-HSCT (35% vs. 10%, p=0.006). Event-free survival at 5 years after a single auto-HSCT depended on the response before HSCT: 40% in VGPR, 10% in PR and 10% in SD/PD. On the contrary, event-free survival at 5 years after double auto-HSCT did not depend on the response before the first auto-HSCT: median EFS were 40, 25, and 22 months in patients who achieved VGPR, PR, and SD/PD (p=0.25) respectively. 

Conclusion: Modern bortezomib-based induction chemotherapy and upfront auto-HSCT provide better OS and EFS in MM.  

Keywords: multiple myeloma, induction chemotherapy, auto-HSCT